Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nocturnal vagus nerve stimulation enhances cognitive functions in patients with early Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same author

Programming in Vagus nerve stimulation therapy: Consensus from a Nordic Delphi Panel.

Seizure·2025
Same author

Statistical Evaluation of Smartphone-Based Automated Grading System for Ocular Redness Associated with Dry Eye Disease and Implications for Clinical Trials.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same author

Drug arrows in the quiver-antiseizure, antiepileptic and neuroprotective medication: Treatment and future aspects. A focused review.

Seizure·2024
Same author

Advantages of Lissamine Green Vital Staining as an Endpoint in Dry Eye Clinical Trials.

Clinical ophthalmology (Auckland, N.Z.)·2024
Same author

Digital clinics for diagnosing and treating migraine.

Current opinion in supportive and palliative care·2024
Same journal

Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.

Epilepsia·2026
Same journal

Outcome trajectories after pediatric epilepsy surgery vary by biopsychosocial phenotypes.

Epilepsia·2026
Same journal

Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.

Epilepsia·2026
Same journal

Long-term mortality after status epilepticus: A 5-year analysis study.

Epilepsia·2026
Same journal

The Epilepsy-Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population-based cohorts in the United States.

Epilepsia·2026
Same journal

Systematic review and meta-analysis of lifestyle modification interventions and their impact on seizure reduction and quality of life.

Epilepsia·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Vigabatrin: 2008 update.

L James Willmore1, Mark B Abelson, Elinor Ben-Menachem

  • 1Department of Neurology and Psychiatry, Saint Louis University School of Medicine, Saint Louis, Missouri 63104, USA.

Epilepsia
|February 21, 2009
PubMed
Summary
This summary is machine-generated.

Vigabatrin (VGB) effectively treats infantile spasms and refractory complex partial seizures by increasing GABA levels. However, regular visual field testing is crucial due to the risk of vision defects, especially with long-term use.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 25, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Area of Science:

  • Neuropharmacology
  • Epileptology
  • Ophthalmology

Background:

  • Vigabatrin (VGB) is a gamma-aminobutyric acid (GABA) analogue that inhibits GABA-transaminase (GABA-T), elevating brain GABA levels.
  • VGB is evaluated for infantile spasms (IS) and refractory complex partial seizures (CPS), showing rapid response in some patients.
  • Potential adverse effects include T2 hyperintensities and rare psychotic disorders, with a notable risk of peripheral visual field defects (VFD).

Purpose of the Study:

  • To assess the efficacy and safety profile of Vigabatrin (VGB) in treating infantile spasms (IS) and refractory complex partial seizures (CPS).
  • To characterize the incidence, prevalence, and progression of VGB-induced peripheral visual field defects (VFD).
  • To establish monitoring guidelines for VGB therapy, balancing therapeutic benefits against visual risks.

Main Methods:

  • Analysis of patient data on VGB treatment for IS and CPS, focusing on seizure response and adverse events.
  • Evaluation of visual field testing results to determine the prevalence and onset of VGB-induced peripheral VFD across different age groups.
  • Review of treatment duration and exposure levels in relation to VFD development.

Main Results:

  • VGB demonstrated rapid efficacy in achieving spasm cessation and reducing seizures in IS and refractory CPS patients.
  • Peripheral VFD prevalence varied by age: 25-50% in adults, 15% in children, and 15-31% retinal defects in infants.
  • VFD onset occurred after 9-11 months of treatment, with a mean exposure of 4.8-5.5 years; central visual acuity was typically preserved.

Conclusions:

  • Cognitive, age-appropriate visual field testing at baseline and regular intervals is mandatory for patients on VGB therapy.
  • Infants require testing at 3-month intervals for 18 months, then every 6 months; adults with CPS need baseline and 6-month interval testing.
  • Physicians must weigh VGB's seizure control benefits against the risk of VFD, discontinuing therapy if no benefit is seen within 12 weeks.